Diabetes mellitus and dementia

Diabetes and Metabolism

Volumn 32, Issue 5, 2006, Pages 403-414

  Pasquier, F ^a,b   Boulogne, A ^b   Leys, D ^b   Fontaine, P ^b  

^a EA 2691   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease; Dementia; Diabetes; Review; Vascular dementia

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; ANTIHYPERTENSIVE AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; GLUCOSE; SOMATOMEDIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD VESSEL REACTIVITY; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CORRELATION ANALYSIS; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLYCEMIC CONTROL; GLYCOSYLATION; HEALTH CARE COST; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MEMORY; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGICAL ANATOMY; QUALITY OF LIFE; REVIEW; VASCULAR DISEASE;

EID: 33751570625     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70298-7     Document Type: Review

References (151)

1. Halter JB. Alzheimer's disease and non-insulin-dependent diabetes mellitus: common features do not make common bedfellows. J Am Geriatr Soc 1996;44:992-3.
2. Bourdel-Marchasson I, Dubroca B, Manciet G, Decamps A, Emeriau JP, Dartigues JF. Prevalence of diabetes and effect on quality of life in older French living in the community: the PAQUID Epidemiological Survey. J Am Geriatr Soc 1997;45:295-301.
3. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996;39:1392-7.
4. Rockwood K, Awalt E, MacKnight C, McDowell I. Incidence and outcomes of diabetes mellitus in elderly people: report from the Canadian Study of Health and Aging. Can Med Assoc J 2000;162:769-72.
5. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S4-S9.
6. Strachan MW, Deary IJ, Ewing FM, Frier BM. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997;20:438-45.
7. Miles WR, Root HF. Psychologic tests applied to diabetic patients. Arch Intern Med 1922; 30:767-77.
8. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999;16:93-112.
9. Lindeman RD, Romero LJ, LaRue A, et al. A biethnic community survey of cognition in participants with type 2 diabetes, impaired glucose tolerance, and normal glucose tolerance: the New Mexico Elder Health Survey. Diabetes Care 2001;24:1567-72.
10. Leys D, Pasquier F. Hypertension artérielle et déclin cognitif. Rev Neurol (Paris) 1999;155:743-8.
11. Bäckman L, Hill RD, Forseel Y. The influence of depressive symptomatology on episodic memory functionning among clinically nondepressed older adults. J Abnorm Psychol 1996;105:97-105.
12. Dufouil C, Fuhrer R, Dartigues JF, Alpérovitch A. Longitudinal analysis of the association between depressive symptomatology and cognitive deterioration. Am J Epidemiol 1996;144:634-41.
13. Desmond DW, Tatemichi TK, Paik M, Stern Y. Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. Arch Neurol 1993;50:162-6.
14. Wahlin A, Nilsson E, Fastbom J. Cognitive performance in very old diabetic persons: the impact of semantic structure, preclinical dementia, and impending death. Neuropsychology 2002;16:208-16.
15. Scott RD, Kritz-Silverstein D, Barrett-Connor E, Wiederholt WC. The association of non-insulin-dependent diabetes mellitus and cognitive function in an older cohort. J Am Geriatr Soc 1998;46:1217-22.
16. Vanhanen M, Kuusisto J, Koivisto K, et al. Type-2 diabetes and cognitive function in a non-demented population. Acta Neurol Scand 1999;100:97-101.
17. Ebly EM, Hogan DB, Parhad IM. Cognitive impairment in the non-demented elderly. Results from the Canadian Study of Health and Aging. Arch Neurol 1995;52:612-9.
18. American Psychiatric Association A. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association 1994.
19. Di Carlo A, Baldereschi M, Amaducci L, et al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. J Am Geriatr Soc 2000;48:775-82.
20. Kalmijn S, Feskens EJM, Launer LJ, Stijnen T, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995;38:1096-102.
21. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004;63:658-63.
22. Croxson SCM, Jagger C. Diabetes and cognitive impairment: a community-based study of elderly subjects. Age Ageing 1995;24:421-4.
23. Carmelli D, Swan GE, Reed T, et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology 1998;50:1580-5.
24. Wechsler D. Manual: Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corp. 1974.
25. Eslinger PJ, Damasio AR, Benton AL. The Iowa battery for mental decline. Iowa City, IA: University of Iowa 1984.
26. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
27. Elias PK, Elias MF, D'Agostino RB, et al. NIDDM and blood pressure as risk factors for poor cognitive performance. Diabetes Care 1997;20:1388-95.
28. Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Arch Intern Med 2000;160:174-80.
29. Knopman D, Boland LL, Mosley T, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001;56:42-8.
30. Frisoni GB, Calabresi L, Geroldi C, et al. Apolipoprotein E ε4 allele in Alzheimer's disease and vascular dementia. Dementia 1994;5:240-2.
31. Hsiung GY, Sadovnik AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. Can Med Assoc J 2004;171:863-7.
32. Carmelli D, Swan GE, Reed T, Wolf PA, Miller BL, DeCarli C. Midlife cardiovascular risk factors and brain morphology in idendical older male twins. Neurology 1999;52:1119-24.
33. Mega MS, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Psychiatr Clin Neurosci 1994;6:358-70.
34. DeCarli C, Murphy DM, Tranh M, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism in 51 healthy adults. Neurology 1995;45:2077-84.
35. Longstreth WTJ, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996;27:1274-82.
36. Wolf-Klein GP, Silverstone FA, Brod MS, et al. Are Alzheimer patients healthier? J Am Geriatr Soc 1988;36:219-24.
37. Landin K, Blennow K, Wallin A, Gottfries C-G. Low blood pressure and blood glucose levels in Alzheimer's disease. Evidence for a hypometabolic disorder? J Intern Med 1993;233:357-63.
38. Tariot PN, Ogden AM, Cox C, Williams F, T. Diabetes and dementia in long-term care. J Am Geriatr Soc 1999;47:423-9.
39. Stewart R. Cardiovascular factors in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1998;65:143-7.
40. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementias and Alzheimer's disease in a defined elderly Japanese population: the Hisayama study. Neurology 1995;45:1161-8.
41. Ott A, Stolk RP, van Harskamp F, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia in an elderly population. In: Ott A, eds. "Risk of Dementia". Delft: Judels En Brinkman BV 1997,49-62.
42. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002;14:77-83.
43. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997;145:301-8.
44. Brayne C, Gill C, Huppert FA, et al. Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 1998;9:175-80.
45. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose intolerance. Neurology 1999;52:971-5.
46. Peila R, Rodriguez BL, Launer LJ, Study. H-AA. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002;51:1256-62.
47. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154:635-41.
48. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
49. Arvanitakis Z, Wilson RS, Bienas JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004;61:661-6.
50. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-92.
51. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Forces on Alzheimer's disease. Neurology 1984;34:939-44.
52. Skoog I. Risk factors for vascular dementia: a review. Dementia 1994;5:137-44.
53. Moncayo J, Bogousslavsky J. Vascular dementia: persisting controversies and questions. Eur J Neurol 1996;3:299-308.
54. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-4.
55. McAlister FA, Zarnke KB, Campbell NR, et al. The 2001 Canadian recommendations for the management of hypertension: Part two - Therapy. Can J Cardiol 2002;18:625-41.
56. Jandeleit-Dahm K, Cooper ME. Hypertension and diabetes. Curr Opin Nephrol Hypertens 2002;11:221-8.
57. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.
58. The CDS Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. J Am Med Assoc 2002;287:2542-51.
59. Forette F, Seux M-L, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51.
60. Celis H, Fagard RH, Staessen JA, Thijs L, Investigators. SHiET. Risk and benefit of treatment of isolated systolic hypertension in the elderly: evidence from the Systolic Hypertension in Europe Trial. Curr Opin Cardiol 2001;16:342-8.
61. Smith NL, Savage PJ, Heckbert SR, et al. Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. J Am Geriatr Soc 2002;50:416-23.
62. Fisman M, Gordon B, Feleki V, Helmes E, McDonald T, Dupre J. Metabolic changes in Alzheimer's disease. J Am Geriatr Soc 1988;36:298-300.
63. Meneilly GS, Hill A. Alterations in glucose metabolism in patients with Alzheimer's disease. J Am Geriatr Soc 1993;41:710-4.
64. Carantoni M, Zuliani G, Munari MR, D'Elia K, Palmieri E, Fellin R. Alzheimer disease and vascular dementia: relationchips with fasting glucose and insulin levels. Dement Geriatr Cogn Disord 2000;11:176-80.
65. Vanhanen M, Soininen H. Glucose intolerance, cognitive impairment and Alzheimer's disease. Curr Opin Neurol 1998;11:673-7.
66. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
67. Calori G, Garancini P, Ruotolo G, Ragogna F, Ruggeria P, Gallus G. Relationship between insulinemia and LDL-cholesterol in non-diabetic subjects: The Cremona population study. Diabetologia 1995;38:A248.
68. Strandberg TE, Tilvis RS, Lindberg O, et al. High plasma insulin associates with lower LDL-cholesterol in elderly individuals. Atherosclerosis 1996;121:267-73.
69. Gold PE. Role of glucose in regulating the brain and cognition. Am J Clin Nutr 1995;61:987S-95S.
70. Craft S, Dagogo-Jack SE, Wiethop BV, et al. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 1993;107:926-40.
71. Hogan DB, Ebly EM, Rockwood K. Weight, blood pressure, osmolarity, and glucose levels across various stages of Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 1997;8:147-51.
72. Foster NL, Hickenbottom SL. When do strokes cause dementia? Effects of subcortical cerebral infaction on cortical glucose metabolism and cognitive function. Arch Neurol 1999;56:778-9.
73. Tatemichi TK, Desmond DW, Paik M, et al. Clinical determinants of dementia related to stroke. Ann Neurol 1993;33:568-75.
74. Censori B, Manara O, Agostinis C, et al. Dementia after first stroke. Stroke 1996;27:1205-10.
75. Loeb C, Gandolfo C, Croce R, Conti M. Dementia associated with lacunar infarction. Stroke 1992;23:1225-9.
76. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology 1996;46:154-9.
77. Inzitari D, Di Carlo A, Pracucci G, et al. Incidence and determinants of poststroke dementia as defined by an informant interview method in a hospital-based stroke registry. Stroke 1998;29:2087-93.
78. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M. Clinical determinants of post-stroke dementia. Stroke 1998;29:75-81.
79. Kase CS, Wolf PA, Kelly-Hayes M, Kannel WB, Beiser A, D'Agostino RB. Intellectual decline after stroke. The Framingham Study. Stroke 1998;29:805-12.
80. Desmond DW, Moroney JT, Paik MC, et al. Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000;54:1124-31.
81. Hénon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D. Postroke dementia: incidence and relationship to prestroke cognitive decline. Neurology 2001;57:1216-22.
82. Woo J, Lam CW, Kay R, Wong AH, Teoh R, Nicholls MG. The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. Arch Neurol 1990;47:1174-7.
83. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432-738.
84. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. PNAS 1992;89:12043-7.
85. Pasquier F, Leys D. Why are stroke patients prone to develop dementia? J Neurol 1997;244:135-42.
86. Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JCr. Increased incidence of neurofibrillary tancles in non-demented individuals with hypertension. J Neurol Sci 1995;131:162-9.
87. De la Torre JC, Mussivand T. Cand disturbed brain microcirculation cause Alzheimer's disease? Neurol Res 1993;15:146-53.
88. Iwamoto N, Nishiyam E, Ohwada J, Arai H. Distribution of amyloid deposits in the cerbral white matter of the Alzheimer's disease brain: relationship to blood vessels. Acta Neuropathol (Berl) 1997;93:334-40.
89. Pluta R, Barcikowska M, Janusezewski S, Misicka A, Lipkowski AW. Evidence of blood-brain barrier permeability/leakage for circulating human Alzheiemr's β-amyloid-(1-42)-peptide. Neuroreport 1996;7:1261-5.
90. Tomimoto H, Akiguchi I, Suenaga T, et al. Alterations of the blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer's disease patients. Stroke 1996;27:2069-74.
91. Hall ED, Oostveen JA, Dunn E, Carter DB. Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils. Exp Neurol 1995;135:17-27.
92. Chew W, Kucharczyk J, Moseley M, Derugin N, Norman D. Hyperglycemia augments ischemic brain injury: in vivo MR imaging/spectroscopic study with nicardipine in cats with occluded middle cerebral arteries. Amer J Neuroradiol 1991;12:603-9.
93. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-91.
94. Dickson DW, Sinicropi S, Yen SH, et al. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol Aging 1996;17:733-43.
95. Takeda A, Yasuda T, Miyata T, et al. Advanced glycation end products co-localized with astrocytes and microglial cells in Alzheimer's disease brain. Acta Neuropathol (Berl) 1998;95:555-8.
96. Mooradian AD. Blood-brain barrier choline transport is reduced in diabetic rats. Diabetes 1987;36:1094-7.
97. Trudeau F, Gagnon S, Massicotte G. Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus. Eur J Pharmacol, 2004;490:177-86.
98. Kuusisto J, Koivisto K, Mykkänen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of the apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997;315:1045-9.
99. Palovcik RA, Phillips MI, Kappy MS, Raizada MK. Insulin inhibits pyramidal neurons in hippocampal slices. Brain Res 1984;309:187-91.
100. Brass BJ, Nonner D, Barrett JN. Differential effects of insulin on choline acetyltransferase and glutamic acid decarboxylase activities in neuron-rich striatal cultures. J Neurochem 1992;59:415-24.
101. Hong M, Lee VM-Y. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997;272:19547-53.
102. Dore S, Kar S, Quirion R. Insuline-like-growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity. PNAS 1997;94:4772-7.
103. Johnson KH, O'Brien TD, Betsholtz C, Westermark P. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med 1989;321:513-8.
104. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004;53:474-81.
105. Edgington SM. Amyloid plaque and diabetes. New research suggests Alzheimer's disease and type II diabetes share a similar pathology. Biotechnol 1994;12:593-4.
106. Kalmijn S, Feskens EJM, Launer LJ, Kromhout D. Cerebrovascular disease, the apolipoprotein ε4 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996;27:2230-5.
107. Stolk RP, Breteler MM, Ott A, et al. Insulin and cognitive function in an elderly population. Diabetes Care 1997;20:792-5.
108. Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001;74:270-80.
109. Liolitsa D, Powell J, Lovestone S. Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;73:261-6.
110. Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 1991;36:343-62.
111. Matyka K, Evans M, Lomas J, Cranston I, MacDonald I, Amiel SA. Altered hierarchy of protective responses against severe hypoglycemia in normal aging and in healthy men. Diabetes Care 1997;20:135-41.
112. Frier BM. Hypoglycaemia and cognitive function in diabetes. Int J Clin Pract 2001;(Suppl. 123):30-37.
113. Reichard P, M. P, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996;39:1483-8.
114. The Diabetes Control and Complications Trial Research Group. Effects of intensive diabetes therapy on neuropsychological functions in adults in the Diabetes Control and Complications Trial. Ann Intern Med 1996;124:379-88.
115. Austin EJ, Deary IJ. A psychometrically validated reanalysis of the Diabetes Control and Complications Trial data. Diabetes Care 1999;22:1273-7.
116. Kramer L, Fasching P, Madl C, et al. Previous episodes of hypoglycemic coma are not associated with permanent cognitive brain dysfunction in IDDM patients on intensive insulin treatment. Diabetes 1998;47:1909-14.
117. Selam JL. Risque cognitif des hypoglycémies répé tées chez le diabétique. Diabetes Metab 1998;24:167-72.
118. Strachan MW, Deary IJ, Ewing FM, Frier BM. Recovery of cognitive function and mood after severe hypoglycemia in adults with insulin-treated diabetes. Diabetes Care 2001;23:305-12.
119. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study. J Am Med Assoc 1997;277:813-7.
120. Wallin A, Sjogren M, A. E, Blennow K, Regland B. Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia;. Eur Neurol 2000;44:229-35.
121. Nagy Z, Esiri MM, Jobst KA, et al. The effects of additional pathology on the cognitive deficit in Alzheimer's disease. J Neuropathol Exp Neurol 1997;56:165-70.
122. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study MC. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169-75.
123. Esiri MM, Wilcock GK, Morris JH. Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 1997;63:749-53.
124. Xuereb JH, Brayne C, Dufouil C, et al. Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann NY Acad Sci 2000;903:490-6.
125. Letenneur L, Launer LJ, Andersen K, et al. Education and the risk for Alzheimer's disease: sex makes difference. EURODEM Incidence Research Group. Am J Epidemiol 2000;151:1064-71.
126. Del Ser T, Hachinski V, Merskey H, Munoz DG. An autopsy-verified study of the effect of education on degenerative dementia. Brain 1999;122:2309-19.
127. Heitner J, Dickson D. Diabetics do not have increased Alzheimer type pathology compared with age-matched control subjects. Neurology 1997;49:1306-11.
128. Uusitupa MIJ, Karhunen L, Rissanen A, et al. Apolipoprotein E phenotype modifies metabolic and hemodynamic abnormalities related to central obesity in women. Am J Clin Nutr 1996;64:131-6.
129. Ukkola O, Kervinen K, Salmela PI, von Dickhoff K, Laasko M, Kesäniemi YA. Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 1993;101:9-15.
130. Nielson KA, Nolan JH, Berchtold NC, Sandman CA, Mulnard RA, Cotman CW. Apolipoprotein-E genotyping of diabetic dementia patients: Is diabetes rare in Alzheimer's disease? J Am Geriatr Soc 1996;44:897-904.
131. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. J Am Med Assoc 1999;282:40-6.
132. Perlmuter LC, Hakami MK, Hodgson-Harrington C, et al. Decreased cognitive function in aging non-insulin-dependent diabetic patients. Am J Med 1984;77:1043-8.
133. Rost K, Roter D, Quill T, Bertakis K. Capacity to remember prescription drug changes: deficits associated with diabetes. Diabetes Res Clin Pract 1990;10:183-7.
134. Rockwood K, Ebly EM, Hachinski V, Hogan D. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurol 1997;54:33-9.
135. Sinclair AJ, Allard I, Bayer A. Observations of diabetes care in long-term institutional settings with measures of cognitive function and dependency. Diabetes Care 1997;20:778-84.
136. Sinclair AJ, Girling AJ, Bayer AJ. Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services. All Wales Research into Elderly (AWARE) Study. Diabetes Res Clin Pract 2000;50:203-12.
137. Cooper ME, Johnston CI. Optimizing treatment of hypertension in patients with diabetes. J Am Med Assoc 2000;283:3177-9.
138. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 1999;56:991-6.
139. Richards SS, Emsley CL, Roberts J, et al. The association between vascular risk-factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans. J Am Geriatr Soc 2000;48:1035-41.
140. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.
141. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-31.
142. Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H. The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 1993;48:M117-M21.
143. Naor M, Steingrüber HJ, Westhoff K, Schottenfeld-Naor Y, Gries AF. Cognitive function in elderly non-insulin-dependent diabetic patients before and after inpatient treatment for metabolic control. J Diabet Complications 1997;11:40-6.
144. UK Prospective Diabetes Study Group Ug. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998,317.
145. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
146. Sirol M, Bouzamondo A, Sanchez P, Lechat P. Does statin therapy reduce the risk of stroke? A meta-analysis. Ann Med Interne (Paris) 2001;152:188-93.
147. Szekacs B, Vajo Z, Varbiro S, et al. Postmenopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension. Br J Obstet Gynaecol 2000;107:1017-21.
148. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline. Evidence of gene-evironment interaction. Neurology 2000;54:1949-53.
149. Maki PM, Zonderman AB, Resnick SM. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry 2001;158:227-33.
150. Carlson MC, Zandi PP, Plassman BL, et al. Hormone replacement therapy and reduced cognitive decline in older women. The Cache County Study. Neurology 2001;57:2210-6.
151. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000;23:542-9.